|Home | About | Journals | Submit | Contact Us | Français|
Osteoporosis is more common in patients with COPD and in smokers. The aim of this study was to assess whether measures of emphysema and airway disease on computed tomography (CT) were associated with lower bone density or vertebral fractures in smokers with and without COPD. For this purpose, we included participants from the NELSON lung cancer screening trial. Bone density was measured as Hounsfield Units in the first lumbar vertebra, and vertebral fractures were assessed semiquantitatively. The 15th percentile method (Perc15) was used to assess emphysema, and the airway lumen perimeter (Pi10) was used for airway wall thickness. Expiratory/inspiratory-ratiomean lung density (E/I-ratioMLD) was used as a measure for air trapping and tracheal index to assess tracheal deformity. Linear regression models and logistic regression models were used to assess associations between CT biomarkers, bone density, and presence of fractures. Exactly 1,093 male participants were eligible for analysis. Lower Perc15 and higher E/I-ratioMLD were significantly associated with lower bone density (b=−1.27, P=0.02 and b=−0.37, P=0.02, respectively). Pi10 and tracheal index were not associated with bone density changes. CT-derived biomarkers were not associated with fracture prevalence. Bone density is lower with increasing extent of emphysema and small airway disease but is not associated with large airway disease and tracheal deformity. This may indicate the necessity to measure bone density early in smokers with emphysema and air trapping to prevent vertebral fractures.
Systemic consequences of COPD, such as cachexia, skeletal muscle wasting, and anemia, significantly contribute to the burden of disease.1,2 The high prevalence of osteoporosis in COPD patients is especially problematic because fractures can lead to substantial disability.3–5
Although the exact pathophysiological relationship between osteoporosis and COPD remains largely unknown, studies have shown similarities between emphysema and osteoporosis in loss of extracellular matrix and associations with inflammatory mediators such as tumor necrosis factor-α.6,7 Also, Ohara et al8 showed that a relationship exists between emphysema and low bone mineral density (BMD) on dual X-ray absorptiometry. However, less is known on the relationship between bone density and airway disease. Computed tomography (CT) is increasingly used to identify biomarkers to classify COPD patients, and it could be helpful in studying the association between morphologic abnormalities underlying COPD and osteoporosis.9 Next to smoking-related lung changes on CT, bone density measurements based on Hounsfield unit (HU) could provide a measure for osteoporosis and are increasingly being investigated as a diagnostic aid.10,11 A recent study showed that bone density measured with CT could be used to identify patients with osteoporosis.12
We hypothesized that lower bone density and vertebral fractures could be found more often in COPD patients with an emphysema-dominant phenotype, compared to COPD patients in whom chronic bronchitis is more evident. This is in line with the hypothesis of an overall wasting COPD phenotype, although these pulmonary and skeletal changes might already be present before COPD is diagnosed.13 Therefore, the purpose of this study was to assess the association of bone density (as a proxy for osteoporosis) and vertebral fractures with several CT quantification measures for lung abnormalities in smokers with and without COPD.
The included participants were part of the Dutch and Belgium Lung Cancer Screening Trial (NELSON trial).14 After gaining information on smoking history, which was derived from questionnaires sent to the general population aged between 50 years and 75 years, participants were invited to participate in the study.15 The NELSON trial included current and former smokers aged between 50 years and 75 years, with a smoking history of at least 16.5 pack-years. Former smokers should not have quit more than 10 years prior to inclusion. Participants were excluded based on self-reported poor health status or if they were unable to climb two flights of stairs, had a recent chest CT scan, had a history of cancer, or a body weight of more than 140 kg. The Ministry of Health of the Netherlands and the institutional ethical review board approved the NELSON trial. The NELSON trial is registered at www.trialregister.nl with trial number ISRCTN63545820 (Institutional Review Board approval number 03/040). Written informed consent was obtained from all participants. A random subset of participants selected from the University Medical Center Utrecht underwent additional lung function tests and expiratory CT and were included in the present study.16 Because of logistical reasons, not all participants underwent lung function testing.
All participants underwent a low-dose paired inspiratory and expiratory volumetric CT scan, which was acquired with 16×0.75 mm collimation (Brilliance 16P; Philips Healthcare, Best, the Netherlands). Scans were made without intravenous contrast injection. For the inspiratory CT, participants weighing 80 kg or less were scanned with 120 kVp at 30 mA, and participants weighing >80 kg were scanned with 140 kVp at 30 mA (estimated effective dose of 1.40 mSv). For the expiratory CT, participants were scanned at 90 kVp (≤80 kg) or 120 kVp (>80 kg) at 20 mA (estimated effective dose of 0.65 mSv). Axial images with a slice thickness of 1.0 mm were reconstructed at 0.7 mm increment using a smooth reconstruction filter (B-filter; Philips Healthcare).
The quantification of emphysema and airway wall thickness has been reported before.17,18 All quantifications were performed with CIRRUS Lung 12.03 (Cirrus, Diagnostic Image Analysis Group, Radboud University Medical Center, Nijmegen, the Netherlands; Fraunhofer MEVIS, Bremen, Germany). The lungs were segmented, and large airways were excluded. Severity of emphysema was assessed with the 15th percentile (Perc15) technique. This technique acquires the HU point below which 15% of the voxels are distributed.19 The closer the Perc15 is to −1,000 HU, the more emphysema is present.
For analysis of large airway disease, the airway lumen was automatically segmented as previously described.20 Airway wall thickness was calculated by the square root of wall area for a theoretical airway with an internal perimeter of 10 mm (Pi10). Airway wall borders were visually inspected to verify correct segmentation.21
CT air trapping was defined as the expiratory to inspiratory ratio of mean lung density (expiratory/inspiratory-ratiomean lung density [E/I-ratioMLD]) and was used as a measure of small airway dysfunction.22 Tracheal index (TI) was measured on inspiratory scans at every slice from 2.5 cm above the bifurcation of the main bronchi to the top of the trachea.23,24 TI was defined by the ratio of coronal and sagittal length of the trachea on the axial plane. Figures 1 and and22 illustrate all CT-derived measurements.
Bone density measurements and fracture assessment have been reported before.25 Bone density measurements were performed in the first lumbar vertebra (L1). If L1 was fractured or not visualized, bone density was measured in a visible adjacent normal vertebra. A region of interest was placed in axial view in the upper part of the vertebra between the endplate and the entrance of the vessels at the anterior midportion, in a homogeneous area of trabecular bone (Figure 3). Regions of interest were as large as possible, and focal heterogeneous areas were avoided. All measurements were taken by a research student (WJ) under the supervision of a chest radiologist (PJ). Vertebral fracture assessment was conducted in a sagittal plane. Height loss of >20% was considered a vertebral facture, compared to an adjacent, nonfractured vertebra. Fracture assessment was executed using semiquantitative method of Genant et al.26
All participants underwent prebronchodilator pulmonary function tests according to the European Respiratory Society/American Thoracic Society guidelines with ZAN equipment (ZAN Messgeräte GmbH, Oberthulba, Germany).27 Forced expiratory volume in 1 second (FEV1) and forced vital capacity were measured. COPD was defined according to the Global Strategy for the Diagnosis, Management, and Prevention of COPD (Global Initiative for Chronic Obstructive Lung Disease).1
Mean and standard deviation (SD) values were calculated for normally distributed data and median and interquartile range for non-normally distributed data. Univariate analyses were used to assess the association of bone density with CT-related COPD measures (Perc15, Pi10, E/I-ratioMLD, and TI) and demographic characteristics (age, body mass index [BMI], smoking status, pack-years, FEV1 % predicted, and COPD status [absent/present]). Biomarkers with a P-value of <0.20 were included in a multivariate linear regression model.
To compare Pi10, Perc15, E/I-ratioMLD, and TI between participants with and without a fracture, a Student’s t-test was performed. Logistic regression was used to study the association of vertebral fractures with Perc15, Pi10, E/I-ratioMLD, and TI, while adjusting for demographic characteristics. A significance level of P<0.05 was considered significant. Statistical Package for the Social Sciences Version 20 was used for all statistical analyses (IBM Corporation, Armonk, NY, USA).
Exactly 1,140 male participants were included with a mean (SD) age of 62.5 (5.3) years. Forty-seven participants were excluded because TI or Pi10 measurements failed, resulting in 1,093 participants analyzed in the current study. Approximately one-third of the participants were classified as having COPD (n=412; 37.7%), and 509 participants (46.6%) were former smokers. Further characteristics of the participants are shown in Table 1. Mean values of Perc15, Pi10, E/I-ratioMLD, and TI are shown in Table 2.
The majority of bone density measurements were performed in L1 (n=938, 85.8%). Because of inhomogeneities and/or fractures in L1 or nonvisualization of L1, 140 measurements were performed in the 12th thoracic vertebra (12.8%), 13 in the eleventh thoracic vertebra (1.2%), and one in the second lumbar vertebra (0.1%). Overall mean (SD) bone density was 105.9 (33.3) HU.
Univariate results are shown in Table 3. Age, pack-years, smoking status, FEV1 % predicted, COPD status, Perc15, and E/I-ratioMLD were included in the multivariate model. BMI, Pi10, and TI were not associated with bone density in univariate analyses. In Table S1, the results of the first multiple linear regression model with bone density as outcome are shown. In this model, pack-years, FEV1 % predicted, and COPD status did not associate independently with bone density. The second and final model included age, smoking status, Perc15, and E/I-ratioMLD (Table 4). With every year of aging, bone density lowers by 1.75 HU (P<0.001). Current smokers have an 8.89 HU lower bone density (P<0.001). When Perc15 lowers by 10 HU, the bone density lowers by 1.27 HU (P=0.02), and when E/I-ratioMLD increases by 1%, the bone density lowers by 0.37 HU (P=0.02).
When comparing the effects of Perc15 and E/I-ratioMLD on bone density by standardization of the effect of one SD change, Perc15 resulted in a 2.42 HU lower bone density and E/I-ratioMLD resulted in a 2.29 HU lower bone density. As an example, Figure 4 includes images of a participant with normal Perc15 and normal bone density and a participant with low Perc15 and low bone density.
Of 1,093 participants, 95 had a vertebral fracture (8.7%). Participants with a fracture had a 1.4 HU lower Perc15 (P=0.02). Pi10, E/I-ratioMLD, and TI were not significantly different in participants with a fracture, compared to those without (P=0.43, P=0.43, and P=0.24, respectively) (Table 2). Table 5 shows the outcomes of the logistic regression analysis. None of the CT-related COPD measures were associated with the presence of a fracture. Only bone density (P<0.01) and smoking status (P=0.03) were associated with the presence of a fracture. For the complete model (Table S2).
The purpose of this study was to assess the association between bone density and morphologic lung changes on CT in heavy smokers. Our data showed that patients with emphysema and air trapping have lower bone density. We did not find an association between airway wall thickness or trachea deformity and bone density. Also, the presence of COPD was not associated with bone density or fracture presence. Thus, low bone density is not disease-specific for COPD, but rather phenotype-specific (emphysema or small airway disease), and could therefore provide relevant prognostic information in a specific group of smokers.
With CT, we are able to directly measure the presence of airway wall thickening from large and medium airways (>2–2.5 mm) by using Pi10 and indirectly measure the presence of air trapping (ie, small airway disease; airways <2 mm) by using E/I-ratioMLD.28 Therefore, Pi10 and E/I-ratioMLD are thought to represent different anatomical parts of the airway tree. In this study, we showed that bone density was associated with emphysema and small airway disease, but airway wall thickening of the larger airway walls was not. The discrepancy between the association of E/I-ratioMLD, Pi10, and bone density might be explained by a difference in underlying systemic processes in small and large airway disease.29
There are several studies that evaluated bone density in participants with COPD. Ohara et al8 used CT measurements to evaluate 65 COPD patients with emphysema and showed that pulmonary emphysema was associated with reduced bone density. Our study confirmed these results in a larger study population, but we also included current and former smoking participants without COPD and evaluated other smoking-related changes such as small airway disease, large airway disease, and trachea deformity, next to emphysema. In this way, the impact of COPD and different characteristics of COPD on bone density could be evaluated. Bon et al30 showed there was a strong and independent association between emphysema and low bone density as well, but they only used visual emphysema scores.
Rutten et al13 demonstrated that fat-free mass index, as a measure of muscle wasting, decreases as the level of emphysema increases in participants with COPD. This relationship was independent of airway wall thickness. Our study complemented these findings by showing an independent association between emphysema and bone density. Moreover, we added E/I-ratioMLD as a measure for air trapping and TI for trachea deformity.
When interpreting the results of the study by Rutten et al combined with the results of our present study, there is an indication that an emphysema phenotype does not only involve destruction of alveolar walls, but also systemic processes that result in destruction of soft tissue and bone.31 While the pathophysiological relationship between tissue inflammation and destruction in the lungs and in the whole body is not confirmed yet, it is hypothesized that an inflammatory response resulting in protease antiprotease imbalance could lead to tissue destruction in both lungs and the whole body.32
A vertebral fracture in COPD patients may interfere with these patients’ already compromised pulmonary function.5 Therefore, early recognition of low bone density in this patient group is of great importance in order to prevent a fracture. Several factors have been reported to contribute to reduced bone density in COPD patients, such as BMI, FEV1, smoking, inactivity, and corticosteroid therapy.33,34 Our results show that smokers with emphysema and air trapping are more at risk for lower bone density than smokers with large airway disease. With this, a specific patient group could be examined and possibly be selected for preventive care.
Our study has limitations. First, our cohort consisted of only male participants with mild emphysema. However, it has been shown that osteoporosis affects men with severe COPD to a similar degree as females, which highlights the importance of early screening in men as well.35 Second, we did not measure fat-free mass or the use of corticosteroid drugs, while both are associated with bone density.36,37 Although fat-free mass could be a better method to evaluate soft tissue loss, BMI has been shown to be correlated with low BMD in patients with COPD.38 Because our population was considered to be relatively healthy, the impact of the use of corticosteroids could be limited. Third, unlike emphysema and airway wall thickening, there is no pathological correlation study available for E/I-ratioMLD as a measure of air trapping. However, several studies have shown that E/I-ratioMLD is the most suitable criterion for assessing small airway disease.21,23,39 Lastly, we only included emphysema, air trapping, and airway wall thickening as CT measures of lung disease but did not include signs of interstitial lung disease, which has been shown to be associated with BMD as well.40,41
This study showed that bone density is significantly lower in smokers with emphysema and small airway disease on CT. It is, however, not associated with large airway wall thickening or trachea deformity. These extrapulmonary skeletal impairments in patients with emphysema and small airway disease support the thought on the existence of a COPD phenotype that also includes systemic characteristics. This may indicate the necessity to measure CT-derived bone density in a specific group of heavy smokers to prevent vertebral fractures.
Bone density is associated with emphysema and air trapping in males with and without COPD.
Eva van Rikxoort received grants from the Netherlands Scientific Organisation during the conduct of the study and is a cofounder and shareholder of Thirona BV. Leticia Gallardo Estrella received grants from the Netherlands Scientific Organisation during the conduct of this study. Bram van Ginneken is a cofounder and shareholder of Thirona BV and received grants from MeVis Medical Systems, Toshiba, and Delft Imaging Systems outside the submitted work. Jan-Willem Lammers received grants from TiPharma and EU during the conduct of this study. The authors report no other conflicts of interest in this work.